glp 1 oral drug With FDA approval of Wegovy pill, new era of GLP-1 weight loss drugs begins Market Overview: GLP-1 Agonists and
Description
Getting your GLP-1 RA prescription filled at a state-licensed pharmacy that dispenses an FDA-approved product is safest

In June 2025, MBX Biosciences announced that it has submitted an IND application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug targeting obesity, which received regulatory clearance in July

however, it will operate outside of the Part D benefit payment flow

The segment is currently dominated by Eli Lilly's weight loss molecule Mounjaro (tirzepatide), which holds about 79% share, while Novo's semaglutide accounts for around 21% as of February-end

The difference is that compounded medications are not manufactured by the original drug company and are not FDA-approved as finished products, though they are legal under specific pharmacy regulations

Endocrinology 152 , 31033112, (2011)